参考文献/References:
[1] Song P,Liu Y,Yu X,et al.Prevalence of epilepsy in China between 1990 and 2015:A systematic review and meta-analysis[J].J Glob Health,2017,7(2):020706.
[2] 吴靖,常丽英,续蕾.194例成人症状性癫痫患者的病因分析[J].卒中与神经疾病,2018,25(3): 316-317.
[3] Kwan P and Brodie M J.Early identification of refractory epilepsy[J].The New England Journal of Medicine,2000,342(5):314-319
[4] Schmidt B.Clinical development of antiepileptic drugs in adults[J]. Neurotherapeutics, 2007,4(1): 62-69.
[5] Krauss GL,Perucca E,Kwan P,et al.Final safety,tolerability,and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials:Study 307[J].Epilepsia,2018,59(4):866-876.
[6] 陈海鹏,马融.女性癫痫患者青春期发作频率变化及其影响因素研究[J].中国中西医结合儿科学,2019,11(3): 198-201.
[7] Blum DE,Eskola J,Bortz JJ,et al.Patient awareness of seizures[J]. Neurology,1996,47(1): 260-264.
[8] Hoppe C,Poepel A,Elger CE.Epilepsy:accuracy of patient seizure counts[J].Arch Neurol, 2007, 64(11):1595-1599.
[9] Inoue Y,Mihara T.Awareness and responsiveness during partial seizures[J]. Epilepsia, 1998,39(suppl 5):7-10.
[10] Kerling F,Mueller S,Pauli E,et al.When do patients forget their seizures? An electroclinical study[J].Epilepsy Behav,2006,9(2):281-285.
[11] Tatum WI,Winters L,Gieron M,et al.Outpatient seizure identification:results of 502 patients using computer-assisted ambulatory EEG[J].J Clin Neurophysiol,2001,18(1):14-19.
[12] 陈伟,施德,刘振国.左乙拉西坦添加治疗青年难治性部分性癫痫患者的效果及对认知功能的影响[J].实用医学杂志,2013,29(3):456-458.
[13] Savitr SV,Arivazhagan A,Sinha S,et al.Clinico-pathological factors influencing surgical outcome in drug resistant epilepsy secondary to mesial temporal sclerosis[J].J Neurol Sci,2014,340(1/2):183-190.
[14] 范甜甜,曾庆意,朱攀,等.常用抗癫痫药初始单药长疗程治疗效果的新指标评价研究[J].药物流行病学杂志,2013,22(12):671-676.
[15] Walker MC,Sander JW.The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal[J].Neurology,1996,46(4):912-914.
[16] Somerville ER,McLaughlin DB,Robinson MK,et al.Adjunctive therapy of uncontrolled partial seizures with levetiracetam in Australian patients[J].Epilepsy Behav,2007,11(3):338-342.
[17] Heo K,Lee BI,Yi SD,et al.Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients [J]. Seizure,2007,16(5):402-409.
[18] Schreiner A,Stollhoff K,Ossig W,et al.Conversion from valproic acid onto topiramate in adolescents and adults with epilepsy[J].Acta Neurol Scand,2009,119(5): 304-312.
[19] Abou-Khalil B,Heimdal P,Privitera MD.An open-label study of levetiracetam at individualized doses between 1000 and 3000 mg day(-1)in adult patients with refractory epilepsy[J].Seizure,2003,12(3):141-149.
[20] Pinto A, Sander JW. Levetiracetam: a new therapeutic option for refractory epilepsy[J]. Int J Clin Pract,2003,57(7):616-621.
[21] Sachdeo RC,Gates JR,Bazil CW,et al.Improved quality of life in patients with partial seizures after conversion to oxcarbazepine monotherapy[J].Epilepsy Behav,2006,9(3):457-463.
[22] Baker G A,Camfield C,Thorbecke R.Commission on outcome measurement in epilepsy,1994-1997:final report[J].Epilepsia,1998,39(2):213-231.
[23] Kwan P,Arzimanoglou A,Berg AT,et al.Definition of drug resistant epilepsy:Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies [J]. Epilepsia,2010,51(6):1069-1077.
[24] French JA,Kanner AM,Bautista J,et al.Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society[J]. Epilepsia, 2004, 45(5):410-423.
[25] Abou-Khalil B,Hemdal P,Privitera MD.An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1)in adult patients with refractory epilepsy[J]. Seizure, 2003,12(3):141-149.
[26] Saetre E,Perucca E,Isojarvi J,et al.An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly[J]. Epilepsia,2007,48(7):1292-1302.
[27] ILAE Commission on Antiepileptic Drugs. Report of the ILAE Commission on Antiepileptic Drugs:Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy[J]. Epilepsia, 1998,39(7):799-803.
[28] European Medicines Agency(EMEA),Committee for Medicinal Products for Human Use(CHMP).Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders.Eur Neuropsychopharmacol,2001,11(3):253-259.
[29] Chung S,Wang N,Hank N.Comparative retention rates and long-term tolerability of new antiepileptic drugs[J]. Seizure,2007,16(4):296-304.
[30] 薛艳玲.传统与新型抗癫痫药物治疗新诊断癫痫患者的一年保留率比较[J].临床医药文献电子杂志,2017,4(92):18173-18174.
[31] Bootsma HP,Ricker L,Diepman L,et al.Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison[J]. Seizure,2008,17(1):19-26.
[32] Bootsma HP,Aldenkamp AP,Diepman L,et al.The effect of antiepileptic drugs on cognition:patient perceived cognitive problems of topiramate versus levetir-acetam in clinical practice[J].Epilepsia,2006,47(Suppl 2):24-27.
[33] Marson AG,Al-Kharusi AM,Alwaidh M,et al.The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy:An unblinded randomised controlled trial[J].Lancet,2007,369(9566):1000-1015.
[34] Marson AG,Al-Kharusi AM,Alwaidh M,et al.The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy:An unblinded randomised controlled trial[J].Lancet,2007,369(9566):1016-1026.
[35] Nicolson A,Lewis SA,Smith DF.A prospective analysis of the outcome of levetiracetam in clinical practice[J].Neurology,2004,63(3):568-570.
[36] Begley CE,Baker GA,Beghi E,et al.Cross-country measures for monitoring epilepsy care[J].Epilepsia,2007,48(5):990-1001.
[37] Chadwick D W.Report of the ILAE commission on antiepileptic drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy[J].Epilepsia,1998,39(7):799-803.
[38] Mattson RH,Cramer JA,Collins JF,et al.Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures[J].N Engl J Med,1985,313(3):145-151.
[39] 王娟,郎森阳,冯杰.癫痫患者的自我效能与生活质量[J].中国临床康复,2006,10(10):142-145.
[40] 岳丽,洪震.癫痫患者的生活质量及其影响因素的研究进展[J].国际神经病学神经外科学杂志,2008,35(1):65-68.
[41] Thomas SV,Koshy S,Nair CR,et al.Frequent seizures and polytherapy can impair quality of Life in persons with epilepsy[J].Neurol India,2005,53(1):46-50.
[42] Guekht AB,Mitrokhina TV,Lebedeva AV,et al.Factors influencing on quality of Life in People with epilepsy[J].Seizure,2007,16(2):130-133.
[43] Vermeire E,Hearnshaw H,Van RP,et al.Patient adherence to treatment: three decades of research.A comprehensive review[J].J Clin Pharm Ther,2001,26(5):331-342.
[44] Urquhart J.Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact[J].Eur Heart J,1996,17(Suppl A):8-15.
[45] 常亮,朱宝玉,常靖,等.癫痫患者疾病经济负担状况[J].中华预防医学杂志,2012,46(12):1084-1087.
[46] Connock M,Frew E,Evans BW,e tal.The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy.A systematic review[J].Health Technol Assess, 2006,10(7): iii,ix-118.